A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
Titel:
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
Auteur:
Lancet, Jeffrey E. Moseley, Anna B. Coutre, Steven E. DeAngelo, Daniel J. Othus, Megan Tallman, Martin S. Litzow, Mark R. Komrokji, Rami S. Erba, Harry P. Appelbaum, Frederick R.